Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v16-EN | Version v14-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2024-06-18 | 2024-06-17 |
| Drug Identification Number | 02541068 | 02541068 |
| Brand name | MOUNJARO | MOUNJARO |
| Common or Proper name | tirzepatide injection | tirzepatide injection |
| Company Name | ELI LILLY CANADA INC | ELI LILLY CANADA INC |
| Ingredients | ||
| Strength(s) | 5MG | 5MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | SUBCUTANEOUS | SUBCUTANEOUS |
| Packaging size | 3 mL single-dose vial | 3 mL single-dose vial |
| ATC code | A10BX | A10BX |
| ATC description | ||
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2023-11-23 | 2023-11-23 |
| Actual start date | 2023-11-23 | 2023-11-23 |
| Estimated end date | 2024-06-17 | 2024-06-17 |
| Actual end date | 2024-06-17 | 2024-06-17 |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Due to continued demand an allocation strategy has been implemented. The mymounjaro™ Patient Support Program (PSP) was designed to provide patients with a seamless and supportive experience and it is an option for Canadian patients. Enrollment into the PSP includes support to find product in a patient’s region, in addition to a number of other resources. The estimated end date represents projected availability at the main Lilly warehouse. Availability dates at a pharmacy’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their distributor to obtain the product availability date at the distributor, or to contact our Lilly Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays) for more information. We are committed to supplying MOUNJARO® for people with type 2 diabetes. Lilly continues to invest and add manufacturing and supply capacity around the world. We are working closely with government entities and other stakeholders to ensure we are doing everything possible to meet the needs of patients with type 2 diabetes. | Due to continued demand an allocation strategy has been implemented. The mymounjaro™ Patient Support Program (PSP) was designed to provide patients with a seamless and supportive experience and it is an option for Canadian patients. Enrollment into the PSP includes support to find product in a patient’s region, in addition to a number of other resources. The estimated end date represents projected availability at the main Lilly warehouse. Availability dates at a pharmacy’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their distributor to obtain the product availability date at the distributor, or to contact our Lilly Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays) for more information. We are committed to supplying MOUNJARO® for people with type 2 diabetes. Lilly continues to invest and add manufacturing and supply capacity around the world. We are working closely with government entities and other stakeholders to ensure we are doing everything possible to meet the needs of patients with type 2 diabetes. |
| Health Canada comments |